Platinum Investment Management Ltd. Trims Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Platinum Investment Management Ltd. lessened its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 9.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,180,295 shares of the company’s stock after selling 344,613 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Gossamer Bio were worth $2,877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of GOSS. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio during the 3rd quarter worth about $67,000. US Bancorp DE acquired a new stake in shares of Gossamer Bio in the 3rd quarter valued at about $39,000. The Manufacturers Life Insurance Company raised its stake in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after acquiring an additional 74,920 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after acquiring an additional 442,895 shares during the last quarter. Finally, Monaco Asset Management SAM raised its stake in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after buying an additional 1,520,721 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Up 2.2 %

NASDAQ GOSS opened at $1.42 on Wednesday. Gossamer Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.55. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The stock has a market cap of $321.78 million, a price-to-earnings ratio of -4.44 and a beta of 1.86. The firm’s 50 day moving average price is $1.14 and its two-hundred day moving average price is $0.97.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analysts’ expectations of $7.02 million. Equities analysts anticipate that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.